Winston-Salem, North Carolina Mar 11, 2008
Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that Alan A. Musso, Vice President and Chief Financial Officer, is scheduled to present at the Cowen and Company 28th Annual Health Care Conference at The Boston Marriott Copley Place on Tuesday, March 18, 2008, at 10:15 a.m. Eastern Daylight Time.
Mr. Musso’s presentation will be webcast and accessible from the Investor Relations section of the Company’s website, http://www.targacept.com. The webcast will also be available for replay on the Company’s website for at least two weeks following the presentation. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer’s disease and cognitive deficits in schizophrenia, depression, and pain, as well as multiple preclinical programs. Targacept has a collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Additional information is available at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 362-3087
Email: michelle@linndencom.com